Literature DB >> 19230018

Precipitation of a monoclonal antibody by soluble tungsten.

Jared S Bee1, Stephanie A Nelson, Erwin Freund, John F Carpenter, Theodore W Randolph.   

Abstract

Tungsten microparticles may be introduced into some pre-filled syringes during the creation of the needle hole. In turn, these microcontaminants may interact with protein therapeutics to produce visible particles. We found that soluble tungsten polyanions formed in acidic buffer below pH 6.0 can precipitate a monoclonal antibody within seconds. Soluble tungsten in pH 5.0 buffer at about 3 ppm was enough to cause precipitation of a mAb formulated at 0.02 mg/mL. The secondary structure of the protein was near-native in the collected precipitate. Our observations are consistent with the coagulation of a monoclonal antibody by tungsten polyanions. Tungsten-induced precipitation should only be a concern for proteins formulated below about pH 6.0 since tungsten polyanions are not formed at higher pHs. We speculate that the heterogenous nature of particle contamination within the poorly mixed syringe tip volume could mean that a specification for tungsten contamination based on the entire syringe volume is not appropriate. The potential potency of tungsten metal contamination is highlighted by the small number of particles that would be required to generate soluble tungsten levels needed to coagulate this antibody at pH 5.0.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19230018      PMCID: PMC2749483          DOI: 10.1002/jps.21707

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  10 in total

Review 1.  Effects of protein aggregates: an immunologic perspective.

Authors:  Amy S Rosenberg
Journal:  AAPS J       Date:  2006-08-04       Impact factor: 4.009

Review 2.  Antibody structure, instability, and formulation.

Authors:  Wei Wang; Satish Singh; David L Zeng; Kevin King; Sandeep Nema
Journal:  J Pharm Sci       Date:  2007-01       Impact factor: 3.534

Review 3.  Immunogenicity of therapeutic proteins. Part 2: impact of container closures.

Authors:  Basant Sharma
Journal:  Biotechnol Adv       Date:  2007-01-30       Impact factor: 14.227

4.  Tungsten-induced protein aggregation: solution behavior.

Authors:  Yijia Jiang; Yasser Nashed-Samuel; Cynthia Li; Wei Liu; Joey Pollastrini; David Mallard; Zai-Qing Wen; Kiyoshi Fujimori; Monica Pallitto; Lisa Donahue; Grace Chu; Gianni Torraca; Aylin Vance; Tony Mire-Sluis; Erwin Freund; Janice Davis; Linda Narhi
Journal:  J Pharm Sci       Date:  2009-12       Impact factor: 3.534

5.  Protein secondary structures in water from second-derivative amide I infrared spectra.

Authors:  A Dong; P Huang; W S Caughey
Journal:  Biochemistry       Date:  1990-04-03       Impact factor: 3.162

Review 6.  The use and misuse of FTIR spectroscopy in the determination of protein structure.

Authors:  M Jackson; H H Mantsch
Journal:  Crit Rev Biochem Mol Biol       Date:  1995       Impact factor: 8.250

7.  2-D and 3-D Interactions in Random Sequential Adsorption of Charged Particles

Authors: 
Journal:  J Colloid Interface Sci       Date:  1997-10-01       Impact factor: 8.128

8.  Loss of factor VIII activity during storage in PVC containers due to adsorption.

Authors:  A G McLeod; I R Walker; S Zheng; C P Hayward
Journal:  Haemophilia       Date:  2000-03       Impact factor: 4.287

9.  The determination of tungsten, molybdenum, and phosphorus oxyanions by high performance liquid chromatography inductively coupled plasma mass spectrometery.

Authors:  A J Bednar; J E Mirecki; L S Inouye; L E Winfield; S L Larson; D B Ringelberg
Journal:  Talanta       Date:  2007-02-20       Impact factor: 6.057

Review 10.  Immunogenicity of therapeutic proteins: clinical implications and future prospects.

Authors:  Huub Schellekens
Journal:  Clin Ther       Date:  2002-11       Impact factor: 3.393

  10 in total
  18 in total

1.  Biotherapeutic formulation factors affecting metal leachables from stainless steel studied by design of experiments.

Authors:  Shuxia Zhou; Brad Evans; Christian Schöneich; Satish K Singh
Journal:  AAPS PharmSciTech       Date:  2012-01-13       Impact factor: 3.246

2.  Chemical modifications in therapeutic protein aggregates generated under different stress conditions.

Authors:  Quanzhou Luo; Marisa K Joubert; Riki Stevenson; Randal R Ketchem; Linda O Narhi; Jette Wypych
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

Review 3.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

4.  Biologics formulation factors affecting metal leachables from stainless steel.

Authors:  Shuxia Zhou; Christian Schöneich; Satish K Singh
Journal:  AAPS PharmSciTech       Date:  2011-03-01       Impact factor: 3.246

5.  Fluorogenic tagging methodology applied to characterize oxidized tyrosine and phenylalanine in an immunoglobulin monoclonal antibody.

Authors:  Shuxia Zhou; Olivier Mozziconacci; Bruce A Kerwin; Christian Schöneich
Journal:  Pharm Res       Date:  2013-02-15       Impact factor: 4.200

6.  Development of biotechnology products in pre-filled syringes: technical considerations and approaches.

Authors:  Advait Badkar; Amanda Wolf; Leigh Bohack; Parag Kolhe
Journal:  AAPS PharmSciTech       Date:  2011-05-04       Impact factor: 3.246

Review 7.  Immunogenicity Risk Assessment for an Engineered Human Cytokine Analogue Expressed in Different Cell Substrates.

Authors:  Paul Chamberlain; Bonita Rup
Journal:  AAPS J       Date:  2020-04-14       Impact factor: 4.009

Review 8.  The importance of handling high-value biologicals: Physico-chemical instability and immunogenicity of monoclonal antibodies.

Authors:  Tomislav Laptoš; Jasna Omersel
Journal:  Exp Ther Med       Date:  2018-01-31       Impact factor: 2.447

9.  Monoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studies.

Authors:  Jared S Bee; David Chiu; Suzanne Sawicki; Jennifer L Stevenson; Koustuv Chatterjee; Erwin Freund; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

Review 10.  Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.

Authors:  Walter H Hörl
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.